Figure 4.

Diagram depicting the action mechanism of dostarlimab against cancer cells. The dostarlimab blocks the interaction of T cells over-expressing PD-1 protein with the PD-L1 present in cancer cells. (A) Cancer cells overexpress PD-L1 on their surface that interact with PD-1 of T cells. This disables the immune system from recognizing and targeting cancer cells. (B) Dostarlimab interacts with the PD-1 receptor on T cells, preventing their interaction with PD-L1 on cancer cells. This restores the T cells’ cytotoxic function, allowing them to detect and kill cancer cells.